Oxidative stress-mediated (sex-specific) loss of protection against type-2 diabetes by macrophage migration inhibitory factor (MIF)-173G/C polymorphism

Clinica Chimica Acta

Volumn 438, Issue , 2015, Pages 1-6

  Coban, Neslihan ^a   Onat, Altan ^a   Yildirim, Ozlem ^a   Can, Gunay ^a   Erginel Unaltuna, Nihan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

ApoB; Diabetes mellitus; Glucose; MIF gene; Polymorphism

Indexed keywords

APOLIPOPROTEIN B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROPHAGE MIGRATION INHIBITION FACTOR; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AGE; ALLELE; ARTICLE; BLOOD GLUCOSE MONITORING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; GLUCOSE BLOOD LEVEL; HUMAN; LOW RISK POPULATION; MACROPHAGE MIGRATION; MALE; MIF GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; DIABETES MELLITUS, TYPE 2; GENETICS; METABOLISM; MIDDLE AGED; ATHEROGENESIS; DIET RESTRICTION; DISEASE ASSOCIATION; DYSLIPIDEMIA; GENETIC RISK; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HETEROZYGOTE; MAJOR CLINICAL STUDY; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; TURK (PEOPLE);

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; OXIDATIVE STRESS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84906240934     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.07.037     Document Type: Article

References (36)

1. David J.R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A 1966, 56:72-77.
2. Calandra T., Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003, 3:791-800.
3. Budarf M., McDonald T., Sellinger B., Kozak C., Graham C., Wistow G. Localization of the human gene for macrophage migration inhibitory factor (MIF) to chromosome 22q11.2. Genomics 1997, 39:235-236.
4. Bernhagen J., Calandra T., Mitchell R.A., et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxemia. Nature 1993, 365:756-759.
5. Calandra T., Bernhagen J., Mitchell R.A., Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994, 179:1895-1902.
6. Burger-Kentischer A., Goebel H., Seiler R., et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 2002, 105:1561-1566.
7. Radstake T.R., Sweep F.C., Welsing P., et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 2005, 52:3020-3029.
8. Wu S.P., Leng L., Feng Z., et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum 2006, 54:3661-3669.
9. Nohara H., Okayama N., Inoue N., et al. Association of the -173G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol 2004, 39:242-246.
10. Atsumi T., Cho Y.R., Leng L., et al. The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation. J Immunol 2007, 179:5399-5406.
11. Dandona P., Aljada A., Ghanim H., et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 2004, 89:5043-5047.
12. Skurk T., Herder C., Kraft I., et al. Production and release of macrophage migration inhibitory factor from human adipocytes. Endocrinology 2005, 146:1006-1011.
13. Yabunaka N., Nishihira J., Mizue Y., et al. Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care 2000, 23:256-258.
14. Herder C., Kolb H., Koenig W., et al. Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4). Diabetes Care 2006, 29:368-371.
15. Sanchez-Zamora Y.I., Rodriguez-Sosa M. The role of MIF in type 1 and type 2 diabetes mellitus. J Diabetes Res 2014, 2014:1-6. 10.1155/2014/804519.
16. Baugh J.A., Chitnis S., Donnelly S.C., et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 2002, 3:170-176.
17. Herder C., Illig T., Baumert J., et al. Macrophage migration inhibitory factor (MIF) and risk for coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Atherosclerosis 2008, 200:380-388.
18. Herder C., Klopp N., Baumert J., et al. Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetologia 2008, 51:276-284.
19. Onat A., Ceyhan K., Başar Ö., Erer B., Toprak S., Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels A prospective and cross-sectional evaluation. Atherosclerosis 2002, 165:285-292.
20. Onat A., Can G., Hergenç G., Küçükdurmaz Z., Uǧur M., Yüksel H. High absolute coronary disease risk among Turks: involvement of risk factors additional to conventional ones. Cardiology 2010, 115:297-306.
21. 10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes and vascular events. J Clin Lipidol 2010, 4:89-98.
22. Onat A., Can G., Çiçek G., Ayhan E., Doǧan Y., Kaya H. Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes and coronary disease in non-diabetic adults. Acta Diabetol 2013, 50:519-528.
23. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001, 156:1-10.
24. Collaboration Emerging Risk Factors, Sarwar N., Gao P., Seshasai S.R., et al. Diabetes mellitus, fasting glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222.
25. Genuth S., Alberti K.G., Bennett P., et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26:3160-3167.
26. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA 2001, 285:2486-2497.
27. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
28. Onat A., Uyarel H., Hergenc G., Karabulut A., Albayrak S., Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007, 191:182-190.
29. Onat A., Can G., Çiçek G., Doǧan Y., Yüksel H. Coronary disease risk and fasting glucose levels in a non-diabetic population. Diabetes Res Clin Pract 2011, 91:220-225.
30. Qi Q., Workalemahu T., Zhang C., et al. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. Eur Heart J 2012, 33:325-334.
31. Onat A., Can G., Örnek E., Sansoy V., Aydin M., Yüksel H. Abdominal obesity with hypertriglyceridemia, lipoprotein(a) and apolipoprotein A-I, determine marked cardiometabolic risk. Eur J Clin Invest 2013, 43:1129-1139.
32. Onat A., Özhan H., Esen A.M., et al. Prospective epidemiologic evidence of a protective effect of smoking on metabolic syndrome and diabetes among Turkish women-without associated overall health benefit. Atherosclerosis 2007, 193:380-389.
33. Rasouli B., Grill V., Midthjell K., et al. Smoking is associated with reduced risk of autoimmune diabetes in adults contrasting with increased risk in overweight men with type 2 diabetes: a 22-year follow-up of the HUNT study. Diabetes Care 2013, 36:604-610.
34. Zernecke A., Bernhagen J., Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation 2008, 117:1594-1602.
35. Velloso L.A., Eizirik D.A., Cnop M. Type 2 diabetes mellitus --an autoimmune disease?. Nat Rev Endocrinol 2013, 9:750-755.
36. Onat A., Can G. Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des 2014, 20:565-574.